Originally published as JCO Early Release 10.1200/JCO.2008.19.0108 on February 17 2009

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Feldman, D. R. Articles by Motzer, R. J. Search for Related Content PubMed PubMed Citation Articles by Feldman, D. R. Articles by Motzer, R. J. Related Articles Related Editorial Social Bookmarking                            What's this?

Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma

From the Departments of Medicine, Epidemiology, Biostatistics, and Radiology, Memorial Sloan-Kettering Cancer Center; and Department of Medicine, Joan and Sanford I. Weill Medical College of Cornell University Medical College, New York, NY.

Corresponding author: Robert J. Motzer, MD, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: motzerr{at}mskcc.org.

Purpose Both bevacizumab and sunitinib target the vascular endothelial growth factor pathway and demonstrate activity against advanced renal cell carcinoma (RCC). In this phase I study, the maximum-tolerated dose (MTD) and safety of sunitinib in combination with bevacizumab were examined in patients with advanced RCC.

Patients and Methods Three cohorts of three to six patients were treated with escalated doses of daily oral sunitinib (ie, 25 mg, 37.5 mg, 50 mg) for 4 weeks followed by a 2-week break and with fixed doses of bevacizumab (10 mg/kg) intravenously once every 2 weeks. Dose-limiting toxicities (DLTs) were assessed during the first cycle to determine the MTD, and an expanded cohort was treated to obtain additional safety information.

Results Of 26 study participants, 25 received treatment at one of three dose levels. Grade 4 hemorrhage, identified as a DLT, occurred in one patient in each of cohorts 2 and 3. The MTD was determined to be sunitinib 50 mg/bevacizumab 10 mg/kg, but chronic therapy at this dose level frequently resulted in grades 3 to 4 hypertension and hematologic and vascular toxicities. Overall, 48% of patients discontinued treatment because of adverse events. One complete and 12 partial responses were observed, which provided an objective response rate of 52%.

Conclusion In this phase I trial of patients with metastatic RCC, the combination of sunitinib and bevacizumab caused a high degree of hypertension and vascular and hematologic toxicities at the highest dose level. We do not plan to pursue additional study of this regimen at these doses in patients with RCC.

Supported by Genentech Inc, South San Francisco, CA.

Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL; and at the 44th Annual Meeting of the American Society of Clinical Oncology Meeting, May 30-June 3, 2008, Chicago, IL.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical Trials repository link available on JCO.org.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• From Theoretical Synergy to Clinical Supra-Additive Toxicity
  Jean-Charles Soria, Christophe Massard, and Hassane Izzedine
  JCO 2009 27: 1359-1361 [Full Text]

This article has been cited by other articles:

				R. J Levine, L. J Vatten, G. L Horowitz, C. Qian, P. R Romundstad, K. F Yu, A. N Hollenberg, A. I Hellevik, B. O Asvold, and S A. Karumanchi Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study BMJ, November 17, 2009; 339(nov17_1): b4336 - b4336. [Abstract] [Full Text] [PDF]

				B. I. Rini, J. A. Garcia, M. M. Cooney, P. Elson, A. Tyler, K. Beatty, J. Bokar, T. Mekhail, R.M. Bukowski, G. T. Budd, et al. A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors Clin. Cancer Res., October 1, 2009; 15(19): 6277 - 6283. [Abstract] [Full Text] [PDF]

				J.-C. Soria, C. Massard, and H. Izzedine From Theoretical Synergy to Clinical Supra-Additive Toxicity J. Clin. Oncol., March 20, 2009; 27(9): 1359 - 1361. [Full Text] [PDF]